-
effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/menopause_research-protocol.pdf
March 25, 2012 - “Colorectal Neoplasms” (mh) OR ((colorectal OR colon) AND (neoplasm* OR cancer OR
carcinoma)) AND … OR ((ovarian OR breast OR colorectal
OR colon OR endometrial) AND (cancer OR cancers OR carcinoma OR … #59 ‘colorectal neoplasms’/exp OR (colorectal OR ‘colon’/exp OR intestinal AND
(‘neoplasm’/exp OR … ‘neoplasms’/exp OR ‘cancer’/exp OR ‘carcinoma’/exp)) AND
[humans]/lim AND [english]/lim AND [embase] … /lim
#60 #17 AND #59
#61 #56 AND #60
Ovarian Cancer
#61 ‘ovarian’/exp AND (‘neoplasm’/exp OR
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/renal-cancer_disposition-comments.pdf
February 24, 2016 - and malignant disease (many
studies included only tumors confirmed to be
cancer). … tumors in the cohort. … applicability
to clinical decision making and the vast majority of patients presenting
with renal cortical neoplasms … The main
point is that larger tumors are associated with
malignancy, and that the OR of 1.3 gives a … who proceeds to surgery as patient or tumor
characteristics (i.e. male sex, larger tumors)
influence
-
effectivehealthcare-admin.ahrq.gov/products/breast-biopsy-update/research-protocol
December 01, 2019 - is the second most common malignancy (after skin cancer), and the second most common cause of cancer … performance outcomes, as assessed by the following measures:
Sensitivity (proportion of cancerous tumors … Cosmetic results
Quality of life
Anxiety and other psychological outcomes
Time to complete tumor … /di or exp breast neoplasms/di or exp breast disease/di or exp breast diseases/di
4
(breast … and ((Biopsy or tumor biopsy).de. or biops$)
7
Large core needle biopsy
6 and ((needle biopsy
-
effectivehealthcare-admin.ahrq.gov/products/anal-cancer-treatment/research
March 01, 2025 - The review covered a diverse set of interventions intended to maximize tumor response while limiting … However, some evidence in advanced gastric and colorectal cancers suggests that capecitabine is noninferior … Risk stratifying tumor characteristics and determining posttreatment relapse patterns could further improve … recommendations based on clinical experience, pragmatism, and extrapolation of findings from other cancers … , and durvalumab) + CRT versus CRT alone, and, finally, one trial examining the role of circulating tumor
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/breast-abnormalities-tests_executive.pdf
February 01, 2006 - Layout 1
Background
Breast cancer is the second most common
malignancy in women. … If a noninvasive diagnostic test
were available that could accurately
exclude malignancy, many women … , each would miss some
cancers. … PET scan, about 924 women would have
avoided an unnecessary biopsy, but 76 women
would have missed cancers … negative
US, about 950 women would have avoided an
unnecessary biopsy, but 50 women would have
missed cancers
-
effectivehealthcare-admin.ahrq.gov/health-topics/radiation-therapy?page=0
August 29, 2023 - It uses high doses of radiation to kill cancer cells and stop them from spreading. … About half of all cancer patients receive it. … The type of radiation therapy you receive depends on many factors, including
The type of cancer … The size of the cancer
The cancer's location in the body
How close the cancer is to normal tissues … and Endobronchial Obstruction Due to Advanced Lung Tumors
Research Protocol Archived
-
effectivehealthcare-admin.ahrq.gov/health-topics/radiation-therapy
August 29, 2023 - It uses high doses of radiation to kill cancer cells and stop them from spreading. … About half of all cancer patients receive it. … The type of radiation therapy you receive depends on many factors, including
The type of cancer … The size of the cancer
The cancer's location in the body
How close the cancer is to normal tissues … and Endobronchial Obstruction Due to Advanced Lung Tumors
Research Protocol Archived
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/colon-cancer-gene-profiling_disposition-comments.pdf
December 14, 2012 - Given what
we know about traditional markers, particularly tumor grade, it is almost
certain that patients … Response is generally reserved for metastatic disease where actual tumor
measurements are possible. … #5 KI Background P 2 . . . patients with MSI-H tumors are excluded. Add the word tumors. … Public Agendia Background P.3 Tumor Heterogeneity (comment) Please note that the impact of tumor
heterogeneity … issue of ASCO Post published a brief summary of
data from this study that were presented at ASCO's GI Cancers
-
effectivehealthcare-admin.ahrq.gov/products/cancer-decision-support-tools/research
December 01, 2019 - Structured Abstract
Background
Many health decisions about screening and treatment for cancers involve … It is unclear whether the effectiveness of decision aids for decisions related to cancers differs by … people's average risk of cancer or by the content and format of the decision aid. … We predefined three population groups of interest based on risk or presence of cancer (average cancer … risk, high cancer risk, early cancer).
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/lung-cancer-staging_executive.pdf
April 01, 2016 - percent
of all lung cancers.3 Despite advances
in diagnosis, treatment, and management
of lung … Lung cancers are classified
based on the size of the main tumor, whether it has locally
invaded other … anatomic sites that harbor
metabolically active malignant areas, FDG-PET helps
distinguish malignant tumors … patient/tumor factor. … the clinical staging of small cell lung
cancer in the forthcoming (seventh) edition of the tumor, node
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/breast-biopsy_disposition-comments.pdf
March 11, 2010 - Introduction p. 11 some of these tumor types aren’t “basic” We have removed the word “basic”. … Diagnoses of malignancy on core-needle
biopsy that cannot be confirmed on open biopsy are
assumed to … Most such tumors would
probably be classified as “invasive” in most of the
studies. … Results The wide range of prevalence of malignancy from 15% to 68.9%
suggests to me that the 15% is … Results p. 50 the evidence seems to suggest a risk of malignancy of much
less than 8%.
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/cancer-survivor-care-transition_research-protocol.pdf
March 27, 2013 - Search "Survivors"[Mesh] OR survivorship OR survivor Filters: Humans; English 498,795
#10 Search "Neoplasms … Search 23257892[uid] 1
#2 Search "Survivors"[Mesh] OR survivorship OR survivor 771137
#3 Search "Neoplasms … #12 Search (#1 AND #9) 0
#13 Search (#1 AND #9) Schema: all 0
Search (("Survivors"[MAJR] AND "Neoplasms … late effects of treatment, second cancers, and poor quality of life, to provide a knowledge base
regarding … optimal followup care and surveillance of cancers, and to optimize health after cancer
treatment.
-
effectivehealthcare-admin.ahrq.gov/products/stereotactic-body-radiation/technical-brief
December 01, 2019 - We synthesized the following variables if reported: cancer type, patient inclusion criteria, type of … The bulk of the studies examined SBRT for tumors of the lung/thorax (k = 68). … We calculated an overall mean and median for the length of followup for each cancer type. … The reported outcomes include tumor control/response, toxicity, and overall survival. … Most studies used four criteria to measure tumor control/tumor response: complete response, partial response
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/care-adults-down-syndrome-protocol.pdf
July 09, 2024 - cancersb Solid tumor cancers, including breast, prostate, testicular,
cervical, and colon cancer. … Low risk of solid tumors in persons with Down
syndrome. … / or exp "Neoplasms, Germ Cell and Embryonal"/ or
(hematologic cancer* or hematologic neoplasms or hematologic … Neoplasms/ or liver neoplasms/ or Prostatic Neoplasms/ or Testicular Neoplasms/ or
Testicular Neoplasms … / or Uterine Cervical Neoplasms/ or ((cancer* or carcinoma?
-
effectivehealthcare-admin.ahrq.gov/products/prostate-cancer-therapies-update/research
December 01, 2019 - Home
Evidence Reports
Therapies for Clinically Localized Prostate Cancer … While the SPCG-4 study found that RP reduced prostate cancer–specific mortality at 12 and 15 years, the … showed reduced all-cause mortality among patients younger than 65 years and among patients with low tumor … mortality was identified among men with prostate-specific antigen >10 ng/mL and among men with intermediate tumor … https://effectivehealthcare.ahrq.gov/products/prostate-cancer-therapies-update/research
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/bladder-cancer-non-muscle-invasive_disposition-comments.pdf
October 27, 2015 - nonmuscle invasive bladder cancer. … On one end of the spectrum are
patients with low grade noninvasive tumors
that rarely develop tumors … implies that cystoscopy is
the gold standard for the identification and
surveillance of urothelial malignancies … related to the pre-test probability of a
urothelial malignancy as AHRQ has done
for the progression … How often will a subsequent work up in
the setting of persistent hematuria reveal a
urothelial malignancy
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/hypofractionated-radiation-therapy-protocol.pdf
April 17, 2024 - as well as limited access to diagnostic tests and treatments for some
populations.4,6,7
Prostate cancers … regimens, with an added subquestion to understand the impact of
pretreatment characteristics, such as tumor … Key Question 3.a Do findings vary with respect to pretreatment characteristics (i.e., tumor
stage, disease … Hypofractionation Radiation Therapy for Definitive
Treatment of Selected Cancers: A Systematic Review … Fiducial markers: Small markers placed in or near the tumor to help guide and precisely target radiation
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/health-equity-protocol.pdf
January 01, 2020 - incidence,
advanced breast cancer,
breast cancer mortality,
and all-cause mortality,
quality-of-life … Breast cancer screening
4. Cervical cancer screening
5. Colorectal cancer screening
6. … / or exp colorectal neoplasms/ or exp lung neoplasms/ or
uterine cervical neoplasms/
25 exp Obesity … / or exp colorectal neoplasms/ or exp lung neoplasms/ or
uterine cervical neoplasms/
25 exp Obesity … / or exp colorectal neoplasms/ or exp lung neoplasms/ or
uterine cervical neoplasms/
25 exp Obesity
-
effectivehealthcare-admin.ahrq.gov/products/health-equity-preventive/protocol
September 01, 2019 - : preventive medication
Breast cancer screening
Cervical cancer screening
Colorectal cancer screening … / or exp colorectal neoplasms/ or exp lung neoplasms/ or uterine cervical neoplasms/
exp Obesity/ … / or exp colorectal neoplasms/ or exp lung neoplasms/ or uterine cervical neoplasms/
exp Obesity/ … exp Colorectal Neoplasms/pc [Prevention & Control]
((colon or colorectal) adj3 cancer).ti,ab,kw. … / or exp colorectal neoplasms/ or exp lung neoplasms/ or uterine cervical neoplasms/
exp Obesity/
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/care-adults-down-syndrome-protocol-amendment.pdf
February 05, 2025 - cancersb Solid tumor cancers, including breast, prostate, testicular,
cervical, and colon cancer. … Low risk of solid tumors in persons with Down
syndrome. … / or exp "Neoplasms, Germ Cell and Embryonal"/ or
(hematologic cancer* or hematologic neoplasms or hematologic … Neoplasms/ or liver neoplasms/ or Prostatic Neoplasms/ or Testicular Neoplasms/ or
Testicular Neoplasms … / or Uterine Cervical Neoplasms/ or ((cancer* or carcinoma?